Abstract
Background
Transcatheter arterial embolization (TAE) has become a therapeutic option for symptomatic polycystic kidney disease (PKD) and polycystic liver disease (PLD). However, factors affecting survival with renal TAE remain unknown.
Methods
All symptomatic patients with severe PKD and/or PLD who received renal and/or hepatic TAE at our center from October 1996 through March 2013 (n = 1,028) were followed until death. Their survival was compared with that of the general PKD population on dialysis in Japan. Factors affecting survival were analyzed using the Cox hazard model.
Results
After renal TAE, 5- and 10-year survival was, respectively, 0.78 (95 % confidence interval, 0.74–0.82) and 0.56 (0.49–0.63); with hepatic TAE, 0.69 (0.58–0.77) and 0.41 (0.22–0.60); and with dual TAE (renal and hepatic), 0.82 (0.72–0.88) and 0.45 (0.31–0.59). Survival after dialysis initiation was better among patients with renal TAE than among general PKD patients. Factors affecting survival after renal TAE were age [hazard ratio (HR) 3.02 (1.44–6.33) for every 10 years] and albumin [HR 0.70 (0.55–0.89) per 0.1 g/dl]. Kidney volume was not associated with patient death after TAE. The main causes of death among patients after renal TAE were similar to those of the general PKD population on dialysis whereas, after hepatic TAE, the main cause was cyst infection with liver failure (12.5 % with PLD and 5.9 % with PKD, p < 0.01).
Conclusion
Survival after renal TAE with severe PKD was better than for the general PKD population on dialysis, suggesting that renal TAE could overcome the disadvantage due to huge organ size.
Similar content being viewed by others
References
Higashihara E, Nutahara K, Kojima M et al (1998) Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron 80:421–427
Davies F, Coles GA, Harper PS, Williams AJ, Evans C, Cochlin D (1991) Polycystic kidney disease re-evaluated: a population-based study. Q J Med 79:477–485
Torres VE, Harris PC (2009) Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 76:149–168
Bae KT, Zhu F, Chapman AB et al (2006) Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 1:64–69
Bistritz L, Tamboli C, Bigam D, Bain VG (2005) Polycystic liver disease: experience at a teaching hospital. Am J Gastroenterol 100:2212–2217
Milutinovic J, Fialkow PJ, Rudd TG, Agodoa LY, Phillips LA, Bryant JI (1980) Liver cysts in patients with autosomal dominant polycystic kidney disease. Am J Med 68:741–744
Grantham JJ, Torres VE, Chapman AB et al (2006) Volume progression in polycystic kidney disease. N Engl J Med 354:2122–2130
Kistler AD, Poster D, Krauer F et al (2009) Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 75:235–241
Temmerman F, Missiaen L, Bammens B et al (2011) Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther 34:702–713
Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407–2418
Ubara Y, Katori H, Tagami T et al (1999) Transcatheter renal arterial embolization therapy on a patient with polycystic kidney disease on hemodialysis. Am J Kidney Dis 34:926–931
Ubara Y, Tagami T, Sawa N et al (2002) Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients. Am J Kidney Dis 39:571–579
Ubara Y, Takei R, Hoshino J et al (2004) Intravascular embolization therapy in a patient with an enlarged polycystic liver. Am J Kidney Dis 43:733–738
Takei R, Ubara Y, Hoshino J et al (2007) Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease. Am J Kidney Dis 49:744–752
Hoshino J, Ubara Y, Suwabe T et al (2014) Intravascular embolization therapy in patients With enlarged polycystic liver. Am J Kidney Dis 63:937
Torres VE (2007) Treatment of polycystic liver disease: one size does not fit all. Am J Kidney Dis 49:725–728
Pei Y, Obaji J, Dupuis A et al (2009) Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 20:205–212
Patient_Registration_Committee (2011) An overview of regular dialysis treatment in Japan (as of 31 December 2011), CD-ROM edition. Japanese Society for Dialysis Therapy, Tokyo
Nakai S, Iseki K, Itami N et al (2012) Overview of regular dialysis treatment in Japan (as of 31 December 2009). Ther Apher Dial 16:11–53
Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K (2012) Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol 16:622–628
Fick GM, Johnson AM, Hammond WS, Gabow PA (1995) Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:2048–2056
Suwabe T, Ubara Y, Sumida K et al (2012) Clinical features of cyst infection and hemorrhage in ADPKD: new diagnostic criteria. Clin Exp Nephrol 16:892
Sherstha R, McKinley C, Russ P et al (1997) Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 26:1282–1286
Park HC, Kim CW, Ro H et al (2009) Transcatheter arterial embolization therapy for a massive polycystic liver in autosomal dominant polycystic kidney disease patients. J Korean Med Sci 24:57–61
Abu-Wasel B, Walsh C, Keough V, Molinari M (2013) Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. World J Gastroenterol 19:5775–5786
Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE (2010) Medical and surgical treatment options for polycystic liver disease. Hepatology 52:2223–2230
Acknowledgments
This work was supported by JH’s research Grants from the Okinaka Memorial Institute, Toranomon Hospital, and The Kidney Foundation, Japan (JKFB13-9), by TS’s Grant from the Japanese Association of Dialysis Physicians (JADP Grant 2013-11), and by YU’s grant from the Okinaka Memorial Institute.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
40620_2014_138_MOESM1_ESM.docx
Supplementary Fig. 1: Overall survival after initiation of dialysis, age-matched analysis. Survival comparison with the general Japanese PKD population on dialysis of our age-matched patients on dialysis who received renal transcatheter arterial embolization (TAE), hepatic TAE, or dual TAE (sequential renal and hepatic TAE) (n = 285, mean age, 64.3 ± 4.9 years). Survival data of the general Japanese PKD population on dialysis is from the annual report (as of 31 December 2011) published by the Japanese Society for Dialysis Therapy (DOCX 103 kb)
Rights and permissions
About this article
Cite this article
Hoshino, J., Suwabe, T., Hayami, N. et al. Survival after arterial embolization therapy in patients with polycystic kidney and liver disease. J Nephrol 28, 369–377 (2015). https://doi.org/10.1007/s40620-014-0138-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-014-0138-0